Ayşe Demirci1, Necati Alkış1, Faysal Dane2, Ayşe Durnalı1, Ömer Kamil Yazıcı1, Rashad Rzayev3, Serap Kaya2, Doğan Yazılıtaş4, Mevlüde İnanç5, Melike Özçelik6, Tülay Akman7, Mehmet Ali Kaplan8, Yusuf Günaydın9, Arife Ulaş10, Özlem Sönmez11, Saadet Tokluoğlu12, Gamze Gököz Doğu13, Öznur Bal1, Mahmut Gümüş6. 1. Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey. 2. Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey. 3. Department of Radiation Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey. 4. Department of Medical Oncology, Konya Training and Research Hospital, Konya, Turkey. 5. Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey. 6. Department of Medical Oncology, Kartal Training and Research Hospital, Istanbul, Turkey. 7. Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine, Izmir, Turkey. 8. Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey. 9. Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey. 10. Department of Medical Oncology, Dr AO Sönmez Oncology Hospital, Bursa, Turkey. 11. Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya, Turkey. 12. Department of Medical Oncology, Güven Hospital, Ankara, Turkey. 13. Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey.
Abstract
AIM: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. METHODS: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. RESULTS: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1-87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4-12 months (Group A), 13-24 months (Group B) and ≥25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow-up duration was 34 ± 30.3 (range, 4-188) months. The OS in patients ≤35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease-free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000). CONCLUSION: There is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use.
AIM: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. METHODS: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancerpatients in Turkey evaluated retrospectively. RESULTS: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1-87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4-12 months (Group A), 13-24 months (Group B) and ≥25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow-up duration was 34 ± 30.3 (range, 4-188) months. The OS in patients ≤35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease-free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000). CONCLUSION: There is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use.